Newsroom
Balsm Alofoq Medical Company Reports 40% Profit Decrease in First Half of 2026
By KlickAnalytics Data Insights | August 31, 2026 06:04PM ET
- Earnings per share (EPS) drop to SAR 0.32 in H1-26 from SAR 0.54 in the previous year.
- Total revenues surge by 17.03% to SAR 11.42 million in H1-26 from SAR 9.76 million in H1-25, attributed to expansion efforts and increased market share.
Despite a significant increase in total revenues, Balsm Alofoq Medical Company announced a 40% decline in net profit, reporting SAR 804,385 in the first half of 2026 compared to SAR 1.34 million in the same period last year. The company's earnings per share (EPS) also fell to SAR 0.32 from SAR 0.54. However, the total revenues witnessed a substantial increase of 17.03%, reaching SAR 11.42 million, driven by the company's expansion strategy and improved market share.
The company justified the drop in profit to higher operating and capital expenses associated with the launch of a new branch and a dermatology department in different locations. Additionally, preparatory costs for a substantial healthcare contract with the Royal Commission for Jubail and Yanbu also affected the bottom line. Balsm Alofoq Medical Company remains optimistic about the strategic investments made, which are expected to boost financial performance and ensure sustainable growth in the upcoming periods.
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with